高级检索
当前位置: 首页 > 详情页

miRNA-34a Suppresses Cell Proliferation and Metastasis by Targeting CD44 in Human Renal Carcinoma Cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Urol,Wuhan 430030,Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Inst Urol,Wuhan 430030,Peoples R China [3]Macao Polytech Inst, Sch Hlth Sci, Macau, Peoples R China [4]Univ Minnesota, Hormel Inst, Dept Cell Death & Canc Genet, Austin, MN 55912 USA [5]Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
出处:
ISSN:

关键词: kidney carcinoma renal cell MIRN34 microRNA human CD44 protein carcinogenesis

摘要:
Purpose: We investigated the potential functions of miR-34a in CD44 transcriptional complexes in renal cell carcinoma. Materials and Methods: We detected miR-34a expression by quantitative real-time polymerase chain reaction. Oligonucleotides were used to over express miR-34a. Cell proliferation and xenograft assays, colony formation and flow cytometry were done to examine effects on cancer cell proliferation in vitro and in vivo. Luciferase assay was performed to verify the precise target of miR-34a. Results: Promoter methylation contributed to miR-34a loss in the ACHN, 786-O and SN12PM6 renal carcinoma cell lines. Ectopic over expression of miR-34a restrained cell growth, tube formation and migration/invasion, and significantly suppressed the growth of renal carcinoma xenografts and metastasis in nude mice. Dual luciferase assay revealed that CD44 was a direct target of miR-34a in renal cancer cells and CD44 knockdown by RNAi in renal cancer cells suppressed tumor progression. In contrast, CD44 ectopic expression partially reversed the antitumor effects of miR-34a in renal cancer cells. Conclusions: Our findings indicate that miR-34a targets CD44 in renal cancer cells and suppresses renal cancer cell growth, tube formation and metastasis in vitro and in vivo. Thus, miR-34a may be a potential molecular target for novel therapeutic strategies for clear cell renal carcinoma.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 2 区 医学
小类 | 2 区 泌尿学与肾脏学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 泌尿学与肾脏学
JCR分区:
出版当年[2012]版:
Q1 UROLOGY & NEPHROLOGY
最新[2023]版:
Q1 UROLOGY & NEPHROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Urol,Wuhan 430030,Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Inst Urol,Wuhan 430030,Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Urol,Wuhan 430030,Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Inst Urol,Wuhan 430030,Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:589 今日访问量:0 总访问量:441 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)